ovarian irradiation
Recently Published Documents


TOTAL DOCUMENTS

23
(FIVE YEARS 0)

H-INDEX

11
(FIVE YEARS 0)

2006 ◽  
Vol 91 (5) ◽  
pp. 1723-1728 ◽  
Author(s):  
Wassim Chemaitilly ◽  
Ann C. Mertens ◽  
Pauline Mitby ◽  
John Whitton ◽  
Marilyn Stovall ◽  
...  

Context: Defined as the loss of ovarian function within 5 yr of diagnosis, acute ovarian failure (AOF) is known to develop in a subset of survivors of pediatric and adolescent cancers. Its precise incidence is unknown, and data concerning its risk factors are limited. Objective: Our objective was to determine the incidence of and patient/treatment factors associated with AOF in a large cohort of pediatric cancer survivors. Design and Setting: We conducted a retrospective cohort, multicenter study. Patients: Female participants from the Childhood Cancer Survivor Study who were greater than 18 yr of age were considered for inclusion. We excluded survivors who received cranial irradiation at doses of more than 3000 cGy, those with hypothalamic/pituitary tumors, and survivors who underwent bilateral oophorectomy. Survivors who reported never menstruating or who had ceased having menses within 5 yr after their cancer diagnosis were considered to have AOF. Main Outcome: We assessed incidence and risk factors for AOF. Results: Of a total of 3390 eligible survivors, 215 cases (6.3%) developed AOF. Survivors with AOF were older at diagnosis and more likely to have been diagnosed with Hodgkin’s lymphoma or to have received abdominal or pelvic radiotherapy than survivors without AOF. Among survivors with AOF, 116 (54%) had received at least 1000-cGy ovarian irradiation. In a multivariable logistic regression model, increasing doses of ovarian irradiation, exposure to procarbazine, and exposure to cyclophosphamide at ages 13–20 yr were independent risk factors for AOF. Conclusions: AOF develops in a small subset of survivors, especially those treated with at least 1000-cGy ovarian radiation. These results will facilitate patient counseling and selection of candidates for newer fertility preservation techniques.


2000 ◽  
Vol 18 (14) ◽  
pp. 2718-2727 ◽  
Author(s):  
F. Boccardo ◽  
A. Rubagotti ◽  
D. Amoroso ◽  
M. Mesiti ◽  
D. Romeo ◽  
...  

PURPOSE: To compare the efficacy of chemotherapy versus that of tamoxifen plus ovarian suppression in pre-/perimenopausal estrogen receptor–positive patients with early breast cancer. PATIENTS AND METHODS: Patients were randomly assigned to receive either six cycles of a standard regimen of cyclophosphamide 100 mg/m2 orally days 1 to 14, methotrexate 40 mg/m2 intravenously (IV) days 1 and 8, and fluorouracil 600 mg/m2 IV days 1 and 8 (CMF), with all drugs restarted on day 29, or 5 years of tamoxifen, 30 mg/d, plus ovarian suppression with surgical oophorectomy, ovarian irradiation, or monthly goserelin 3.6-mg injections. Disease-free survival was the main study end point. Overall survival and toxicity were additional end points. RESULTS: Between 1989 and 1997, 120 patients were assigned to CMF and 124 to tamoxifen and ovarian suppression (oophorectomy, n = 6; ovarian irradiation, n = 31; and goserelin injections, n = 87). At the time of analysis (median follow-up time, 76 months; range, 9 to 121 months), 82 patients had relapsed and 39 had died. No difference between groups had emerged with respect to either disease-free or overall survival. Treatments were comparable even in respect to age, tumor size, and nodal status, although a nonsignificant trend favored patients with poorly differentiated tumors treated with CMF. Leukopenia, nausea, vomiting, stomatitis, and alopecia were significantly more common in patients treated with CMF. There were few patients who developed benign gynecologic changes in either group, and numbers were comparable. CONCLUSION: The combination of tamoxifen with ovarian suppression seems to be safe and to yield comparable results relative to standard CMF.


1996 ◽  
Vol 37 (1) ◽  
pp. 11-19 ◽  
Author(s):  
J. W. Meakin ◽  
J. L. Hayward ◽  
T. Panzarella ◽  
W. E. C. Allt ◽  
F. A. Beale ◽  
...  

1991 ◽  
Vol 5 (4) ◽  
pp. 385-388 ◽  
Author(s):  
John F. Jarrell ◽  
Avril McMahon ◽  
Ronald D. Barr ◽  
Edward V. YoungLai

1983 ◽  
Vol 3 (S1) ◽  
pp. S45-S48 ◽  
Author(s):  
J. W. Meakin ◽  
W. E. C. Allt ◽  
F. A. Beale ◽  
R. S. Bush ◽  
R. M. Clark ◽  
...  

The Lancet ◽  
1975 ◽  
Vol 305 (7903) ◽  
pp. 401
Author(s):  
Michael Alderson

1966 ◽  
Vol 97 (4) ◽  
pp. 951-956 ◽  
Author(s):  
MARIO M. VUKSANOVIC
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document